次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

非小細胞肺がん治療薬の世界市場:研究開発動向と2025年市場予測

NON-SMALL CELL LUNG CANCER DRUGS: MARKET, COMPANIES AND R&D OUTLOOK 2015-2025

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2015年10月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文172ページになります。
商品コード:VGN469

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
非小細胞肺がん治療薬の世界市場規模は2019年に88億ドルに達し、2025年にかけて拡大が見込まれます。
当レポートでは、2015年から2025年に至る非小細胞肺がん(NSCLC)治療薬の世界市場予測、セグメント別市場(化学療法、EGFR/ALK阻害剤、VEGF/VEGFR、免疫療法)、主要製品別売上予測(Alimta (pemetrexed)、Avastin (bevacizumab)、Tarceva (erlotinib)、Iressa (gefitinib)等、全11ブランド)、主要国別市場などの詳細予測データと分析を掲載しています。また研究開発動向(9製品候補)、市場動向分析、業界企業オピニオンなどの調査解説を交えて、今後の市場機会と展望を検討していきます。

【レポート構成概要】VGN469_pic Iressa-NSCLC-Forecast-Revenues.jpg
◆非小細胞肺がん(NSCLC)治療薬の世界市場予測2015-2025年

◆セグメント別市場予測-2025および分析
・化学療法
・EGFR / ALK阻害剤
・VEGF / VEGFR
・免疫療法。

◆主要製品別、売上予測2015-2025および分析
(※以下11ブランド掲載)
・Alimta (pemetrexed) by Eli Lilly
・Avastin (bevacizumab) by Roche
・Tarceva (erlotinib) by Roche
・Iressa (gefitinib) by AstraZeneca
・Gilotrif (afatinib) by Boehringer Ingelheim
・Xalkori (crizotinib) by Pfizer
・Abraxane (paclitaxel Protein-Bound) by Celgene
・Taxotere (docetaxel) by Sanofi
・Cyramza (ramucirumab) by Eli Lilly
・Zykadia (ceritinib) by Novartis
・Opdivo (nivolumab) by Bristol-Myers Squibb.

◆主要11ヶ国、国別市場予測-2025年と分析
・米国
・日本
・ドイツ、フランス、英国、イタリア、スペイン
・ブラジル、ロシア、インド、中国

◆研究開発(R&D)パイプライン、動向と進展
(※以下9製品候補を掲載)
・Alecensa (alectinib) by Roche
・Vargatef (nintedanib) by Boehringer Ingelheim
・AZD9291 by AstraZeneca
・Rociletinib (CO-1686) by Clovis Oncology
・Keytruda (pembrolizumab) by Merck (MSD)
・Ganetespib (STA-9090) by Synta Pharmaceuticals
・Halaven (eribulin) by Eisai
・Necitumumab by Eli Lilly
・Atezolizumab (MPDL3280A) by Roche.

◆市場動向
・遺伝子変異が可能にする標的治療
・ステージ別の治療プロトコル:メンテナンス、セカンドライン、サードライン
・当局規制、コスト効果、価格設定と費用償還
・直近承認動向、治療オプションの拡大
・特許失効の克服とジェネリック薬との競合

◆業界企業オピニオンインタビュー:
- Novartis

◆調査結論
(全172ページ、83個のデータ表、49個のチャート類)

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

NON-SMALL CELL LUNG CANCER DRUGS: MARKET, COMPANIES AND R&D OUTLOOK 2015-2025

Table of Contents

1. Report Overview

1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to NSCLC and its Treatment

2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy

3. Leading NSCLC Drugs, 2015-2025

3.1 Alimta (pemetrexed) by Eli Lilly - The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent - Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2014
3.1.6 Alimta for NSCLC, 2014
3.1.7 Alimta for NSCLC Forecast, 2015-2025
3.2 Avastin (bevacizumab) - Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC - Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2014
3.2.5 Avastin for NSCLC Forecast, 2015-2025
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva - and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2014
3.3.5 Tarceva for NSCLC Forecast, 2015-2025
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2014
3.4.3 Iressa for NSCLC Forecast, 2015-2025
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2014
3.6.5 Xalkori for NSCLC Forecast, 2015-2025
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2014
3.7.5 Abraxane for NSCLC Forecast, 2015-2025
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2014
3.8.4 Taxotere for NSCLC Forecast, 2015-2025
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2015-2025
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2015-2025
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2015-2025

4. NSCLC R&D Pipeline, 2015-2025

4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.4 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
4.3.2 Collaboration with Roche to Develop Companion Diagnostic
4.3.3 Positive Preliminary Results Presented at ASCO 2015
4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC

5. Global NSCLC Market, 2015-2025

5.1 The Global NSCLC Market Forecast, 2015-2025
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market

6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market

6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
6.1.1 Therapeutic Segments Forecast, 2015-2025
6.1.2 Chemotherapy Segment Forecast, 2015-2025
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
6.1.5 Immunotherapy Segment Forecast, 2015-2025
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
6.2.3 US NSCLC Market, 2015-2025
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2015-2025
6.2.4 EU5 NSCLC Market, 2015-2025
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2015-2025
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2015-2025
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2015-2025
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
6.2.6 BRIC NSCLC Market, 2015-2025
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2015-2025
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2015-2025

7. Research Interview

7.1 Interview with Novartis
7.1.1 On the Need for More than one ALK Inhibitor on the Market
7.1.2 Main Trends and Opportunities for NSCLC
7.1.3 The Present and the Future

8. Conclusions from Our Research and Analysis

8.1 How Will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks

List of Tables

Table 1.1 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Example NSCLC First-Line Therapy Options for the Different Patient Populations
Table 3.1 FDA-Approved Indications for Alimta, 2004-2009
Table 3.2 Patent Expiries for Alimta, 2015-2022
Table 3.3 Total Alimta Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.4 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.5 Alimta for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.6 FDA-Approved Indications for Avastin, 2004-2014
Table 3.7 Total Avastin Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.8 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.9 Avastin for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.10 FDA-Approved Indications for Tarceva, 2004-2013
Table 3.11 Total Tarceva Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.12 Tarceva NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.13 Tarceva for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.14 Total Iressa Revenues ($bn), 2010-2014
Table 3.15 Iressa NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.16 Iressa for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.17 Gilotrif NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.18 Gilotrif for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.19 Total Xalkori Revenues ($bn), AGR (%), CAGR (%), 2012-2014
Table 3.20 Xalkori NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.21 Xalkori for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.22 FDA-Approved Indications for Abraxane, 2005-2013
Table 3.23 Total Abraxane Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.24 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.25 Abraxane NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.26 FDA-Approved Indications for Taxotere, 1999-2006
Table 3.27 Total Taxotere Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 3.28 Taxotere NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.29 Taxotere for NSCLC Forecast: Revenues ($bn), AGR (%),CAGR (%), 2020-2025
Table 3.30 FDA-Approved Indications for Cyramza, 2014-2015
Table 3.31 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.32 Cyramza NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.33 FDA-Approved Indications for Abraxane, 1996-2006
Table 3.34 Zykadia NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.35 Zykadia for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 3.36 Opdivo NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 3.37 Opdivo for NSCLC Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 4.1 Currently Ongoing Clinical Trials Involving Alectinib in NSCLC
Table 4.2 Selected Ongoing Clinical Trials Involving Vargatef in NSCLC
Table 4.3 Selected Ongoing Clinical Trials Involving AZD9291 in NSCLC
Table 4.4 Ongoing Clinical Trials Involving Rociletinib in NSCLC
Table 4.5 Selected Ongoing Clinical Trials Involving Keytruda in NSCLC
Table 4.6 Ongoing Clinical Trials Involving Ganetespib in NSCLC
Table 4.7 Clinical Trials Involving Halaven in NSCLC
Table 4.8 Selected Ongoing Clinical Trials Involving Necitumumab in NSCLC
Table 4.9 Ongoing Clinical Trials Involving Atezolizumab in NSCLC
Table 5.1 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2019
Table 5.2 Global NSCLC Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2020-2025
Table 6.1 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.2 Therapeutic Segments within the NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.3 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.4 Chemotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.6 EGFR and ALK Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.7 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.8 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.9 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.10 Immunotherapy Segment: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.11 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.12 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.13 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.14 US NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.15 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.16 German NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.17 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.18 French NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.19 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.20 Italian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.21 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.22 UK NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.23 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.24 Spanish NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.25 Japanese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.26 Japanese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.27 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.28 Chinese NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.29 Brazilian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.30 Brazilian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.31 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.32 Russian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025
Table 6.33 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2019
Table 6.34 Indian NSCLC Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2025

List of Figures

Figure 2.1 Example Adjuvant Chemotherapy Regimens for NSCLC in Stage 1 or Stage 2
Figure 2.2 Example Chemotherapy Regimens for Use in Concurrent Chemotherapy / Radiation in Stage 3 NSCLC
Figure 2.3 Example Chemotherapy Regimens for use in Stage 4 NSCLC
Figure 3.1 Total Alimta Revenues ($bn), 2010-2014
Figure 3.2 Alimta for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.3 Total Avastin Revenues ($bn), 2010-2014
Figure 3.4 Avastin for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.5 Total Tarceva Revenues ($bn), 2010-2014
Figure 3.6 Tarceva for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.7 Total Iressa Revenues ($bn), 2010-2014
Figure 3.8 Iressa Revenues Regional Breakdown: Revenues ($bn), Market Share (%), 2014
Figure 3.9 Iressa for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.10 Gilotrif for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.11 Total Xalkori Revenues ($bn), 2012-2014
Figure 3.12 Xalkori for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.13 Total Abraxane Revenues ($bn), 2010-2014
Figure 3.14 Abraxane for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.15 Total Taxotere Revenues ($bn), 2010-2014
Figure 3.16 Taxotere for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.17 Cyramza for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.18 Zykadia for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 3.19 Opdivo for NSCLC Forecast: Revenues ($bn), 2015-2025
Figure 5.1 Global NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 5.2 SWOT Analysis of Global NSCLC Market, 2015
Figure 6.1 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2015
Figure 6.2 Therapeutic Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2025
Figure 6.3 Therapeutic Segments within the NSCLC Market: Revenues ($bn), 2015-2025
Figure 6.4 Chemotherapy Segment: Revenues ($bn), 2015-2025
Figure 6.5 EGFR and ALK Inhibitors Segment: Revenues ($bn), 2015-2025
Figure 6.6 VEGF / VEGFR Inhibitors Segment: Revenues ($bn), 2015-2025
Figure 6.7 Immunotherapy Segment: Revenues ($bn), 2015-2025
Figure 6.8 Regional Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2015
Figure 6.9 Regional Composition of the Global NSCLC Market: Revenues ($bn), Market Share (%), 2025
Figure 6.10 Regional Forecasts for the Global NSCLC Market: Revenues ($bn), 2015-2025
Figure 6.11 US NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.12 German NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.13 French NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.14 Italian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.15 UK NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.16 Spanish NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.17 Japanese NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.18 Chinese NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.19 Brazilian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.20 Russian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 6.21 Indian NSCLC Market Forecast: Revenues ($bn), 2015-2025
Figure 8.1 Global NSCLC Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2015-2025
Figure 8.2 Breakdown by Submarket: Revenues ($bn), 2015-2025
Figure 8.3 Leading National Markets: Revenues ($bn), 2014
Figure 8.4 Leading National Markets: Revenues ($bn), 2025

掲載企業リスト

Companies Listed

Abbott
Abraxis
Actavis
American Cancer Society
American Society of Clinical Oncology
Amgen
Apotex
AstraZeneca
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chiba University Hospital (Japan)
Chugai
Clovis Oncology
Committee for Medicinal Products for Human Use (CHMP)
Eisai
Eli Lilly
EMD Serono
European Commission
European Medicines Agency (EMA)
European Union (EU)
German Institute for Quality and Efficiency in Health Care (IQWiG)
Hospira
Merck (MSD)
Merck KGaA
Ministry of Health, Labour and Welfare (MHLW, Japan)
National Comprehensive Cancer Network (NCCN)
Novartis
Oanda
Oncologic Drugs Advisory Committee (ODAC)
Pfizer
Qiagen
Roche
Roche Molecular Systems Inc
Sanofi
Swiss Re
Synta Pharmaceuticals
Teva
The Court of Appeal (England)
The European Federation of Pharmaceutical Industries and Associations (EFPIA)
The High Court (England)
The National Health Service (NHS, England)
The National Institute for Health and Care Excellence (NICE)
US Court of Appeals
US Food and Drug Administration (FDA)
World Health Organization (WHO)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。